Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. In addition, the company focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Septerna, Inc.

Deutsche Bank analyst James Brand reiterated a Buy rating on SSE today and set a price target of p2,650.00. According to TipRanks, Brand is a 5-sta...

Deutsche Bank  Remains a Buy on SSE (SSE)

An announcement from SSE ( ($GB:SSE) ) is now available. SSE plc has reported that 22,138 shareholders elected to receive the final dividend for th...

SSE Cuts Dividend Cash Outlay and Moves to Offset Scrip Dilution With Share Buyback

An announcement from Septerna, Inc. ( ($SEPN) ) is now available. Septerna, Inc., a clinical-stage biotechnology company specializing in GPCR-targe...

Septerna Appoints Rajiv Patni as Chief Medical Officer

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Septerna, Inc. today and set a price target of $46.00. According to TipRanks, ...

Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Septerna, Inc. yesterday and set a price target of $59.00. Devarakonda cov...

Truist Financial Reaffirms Their Buy Rating on Septerna, Inc. (SEPN)

There’s a lot to be optimistic about in the NA sector as 3 analysts just weighed in on MBX Biosciences, Inc. (MBX), Septerna, Inc. (SEPN) and Six F...

Analysts Offer Insights on NA Companies: MBX Biosciences, Inc. (MBX), Septerna, Inc. (SEPN) and Six Flags Entertainment Corporation (FUN)

In a report released today, Derek Archila from Wells Fargo reiterated a Buy rating on Septerna, Inc., with a price target of $50.00. According to T...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SEPN	$36.75	-0.14%	199.66K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SEPN	$36.75	-0.1%	199.66K
3
4
5
6

SEPN

Get Septerna, Inc. Data in Excel

Get Septerna, Inc. Data in Excel